Cargando...
PS1-30: Cost-Effectiveness Analysis of Screening for Kras and Braf Genetic Mutations in Metastatic Colorectal Cancer
BACKGROUND/AIMS: In the case of metastatic colorectal cancer (mCRC) there is sufficient evidence to show that significantly more effective and expensive anti-Epidermal Growth Factor Receptor (anti-EGFR) monoclonal antibodies like Cetuximab and Panitumumab are effective only if the patient does not h...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Marshfield Clinic
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3251375/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.1020.ps1-30 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|